Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey

dc.contributor.author	Yusuf, Salim
dc.contributor.author	Islam, Shofiqul
dc.contributor.author	Chow, Clara K.
dc.contributor.author	Rangarajan, Sumathy
dc.contributor.author	Rahman, Omar
dc.contributor.author	et al
dc.date.accessioned	2013-03-31T13:15:45Z
dc.date.available	2013-03-31T13:15:45Z
dc.date.issued	2011-08-28
dc.identifier.citation	Yusuf, S. et al (2011). Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet, 378: pp.1231-1243	UTF-8
dc.identifier.uri	https://ar.iub.edu.bd/handle/11348/166
dc.description.abstract	The research was aimed to assess use of proven eff ective secondary preventive drugs (antiplatelet drugs, β blockers, angiotensin-converting-enzyme [ACE] inhibitors or angiotensin-receptor blockers [ARBs], and statins) in individuals with a history of coronary heart disease or stroke.	UTF-8
dc.language.iso	en	UTF-8
dc.publisher	Lancet	UTF-8
dc.subject	Cardiovascular disease	UTF-8
dc.subject	Epidemiology	UTF-8
dc.subject	Surveys	UTF-8
dc.subject	Drugs	UTF-8
dc.subject	Income levels	UTF-8
dc.subject	Rural areas	UTF-8
dc.subject	Urban Areas	UTF-8
dc.subject	Angiotensin	UTF-8
dc.title	Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey	UTF-8
dc.type	Article	UTF-8